Halozyme Announces Positive Opinion from CHMP On Roche's Herceptin SC for...
My news for Investors AtLeast one of the check box should be selected You are following news about Follow the latest news about HALO Download image Halozyme Therapeutics, Inc. Logo....
View ArticleHalozyme Announces Positive Opinion from CHMP On Roche's Herceptin SC for...
(Source: Halozyme Therapeutics Inc) SAN DIEGO, June 28, 2013/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that Roche received a positive recommendation from the European...
View ArticleHalozyme Announces Positive Opinion from CHMP On Roche's Herceptin SC...
SAN DIEGO, June 28, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO) announced today that Roche received a positive recommendation from the European Medicines Agency's Committee for Medicinal...
View ArticleViroPharma And Halozyme Provide Update On Clinical Development Of...
EXTON, Pa. and SAN DIEGO, Sept. 21, 2012 /PRNewswire/ -- ViroPharma Incorporated (VPHM) and Halozyme Therapeutics, Inc. announced today that the U.S. Food & Drug Administration (FDA) has provided...
View ArticleViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2b Dose...
My news for Investors AtLeast one of the check box should be selected You are following news about Follow the latest news about VPHM Follow the latest news about HALO Google...
View ArticleViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2b Dose...
EXTON, Pa., Dec. 19, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) and Halozyme Therapeutics (Nasdaq: HALO) announced today that ViroPharma has initiated its Phase 2b double blind,...
View ArticleHalozyme Announced Roche Filed A Marketing Authorization Application For...
Filing Triggered a $4 Million Milestone Payment to Halozyme From Roche Data From Subcutaneous MabThera Trials Presented at the American Society of Hematology Annual Meeting SAN DIEGO, Dec. 8, 2012...
View ArticleHalozyme Reports Third Quarter 2012 Financial Results
SAN DIEGO, Nov. 8, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the quarter ended September 30, 2012. (Logo:...
View ArticleHalozyme Therapeutics And Pfizer Enter Into A Collaboration To Develop And...
My news for Investors AtLeast one of the check box should be selected You are following news about Follow the latest news about PFE Follow the latest news about HALO Google Download image...
View ArticleHalozyme Therapeutics And Pfizer Enter Into A Collaboration To Develop And...
SAN DIEGO, Dec. 21, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that it has entered into a worldwide Collaboration and License Agreement with Pfizer Inc. (NYSE:...
View ArticleHalozyme Reports Second Quarter 2013 Financial Results (Halozyme...
(Source: Halozyme Therapeutics Inc) 08/07/2013 SAN DIEGO, Aug. 7, 2013/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the quarter and six months ended...
View ArticleHalozyme Provides Update on ViroPharma Phase 2 Trial of Subcutaneous Cinryze...
SAN DIEGO, Aug. 1, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO) announced that following discussions with the Center for Biologics Evaluation and Research (CBER) division of the U.S. Food...
View ArticleHalozyme Provides Update on ViroPharma Phase 2 Trial of Subcutaneous Cinryze...
(Source: Halozyme Therapeutics Inc) 08/01/2013 SAN DIEGO, Aug. 1, 2013/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that following discussions with the Center for Biologics...
View ArticleHalozyme Announces Roche Receives Marketing Authorization for Herceptin SC...
(Source: Halozyme Therapeutics Inc) SAN DIEGO, Sept. 2, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the European Commission has granted Roche European Union...
View ArticleHalozyme Announces Roche Receives Marketing Authorization for Herceptin SC...
SAN DIEGO, Sept. 2, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO) announced today that the European Commission has granted Roche European Union (EU) marketing authorization for the use of a...
View ArticleYale Researchers Initiate Clinical Trial Evaluating Halozyme's Recombinant...
My news for Investors AtLeast one of the check box should be selected You are following news about Follow the latest news about HALO Download image Halozyme Therapeutics, Inc. Logo....
View ArticleYale Researchers Initiate Clinical Trial Evaluating Halozyme's Recombinant...
(Source: Halozyme Therapeutics Inc) SAN DIEGO, Oct. 15, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today the first patient has been dosed in a closed loop control...
View ArticleYale Researchers Initiate Clinical Trial Evaluating Halozyme's Recombinant...
SAN DIEGO, Oct. 15, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today the first patient has been dosed in a closed loop control ("artificial pancreas") clinical study...
View ArticleHalozyme Reports Third Quarter 2013 Financial Results (Halozyme Therapeutics...
(Source: Halozyme Therapeutics Inc) 11/08/2013 SAN DIEGO, Nov. 8, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the third quarter and nine months...
View ArticleHalozyme Reports Third Quarter 2013 Financial Results
SAN DIEGO, Nov. 8, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the third quarter and nine months ended September 30, 2013. Financial highlights...
View ArticleCommercial Launch of Herceptin SC in EU Triggers Milestone Payment to...
(Source: Halozyme Therapeutics Inc) SAN DIEGO, Sept. 26, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the commercial launch of Herceptin® SC in Europe has...
View ArticleCommercial Launch of Herceptin SC in EU Triggers Milestone Payment to...
SAN DIEGO, Sept. 26, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO) today announced that the commercial launch of Herceptin® SC in Europe has triggered a $10 million milestone payment to...
View ArticleHalozyme Therapeutics Provides an Update on Anticipated Milestones for 2014...
(Source: Halozyme Therapeutics Inc) SAN DIEGO, Jan. 13, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today provided an update on the anticipated milestones for its product...
View ArticleHalozyme Announces Positive Opinion From CHMP For European Approval Of...
SAN DIEGO, Jan. 24, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has recommended that the European...
View ArticleHalozyme Announces Positive Opinion From CHMP For European Approval Of...
(Source: Halozyme Therapeutics Inc) SAN DIEGO, Jan. 24, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the EU Committee for Medicinal Products for Human Use (CHMP)...
View ArticleBaxter and Halozyme Announce Positive Opinion for HyQvia for Treatment of...
LONDON--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the European Medicines Agency’s Committee for Medicinal Products for...
View ArticleHALOZYME JUMPS ON PRODUCT NEWS
Shares of Halozyme Therapeutics jumped 25 percent Friday after a favorable decision from a European regulatory committee. A reformulated version of Roche’s drug Herceptin made with Halozyme technology...
View ArticleHalozyme Announces Roche Marketing Authorization For MabThera SC For Patients...
MabThera SC offers a faster administration time for patients in Europe while potentially saving valuable time for health systems My news for Investors AtLeast one of the check box should be selected...
View ArticleHalozyme Announces Roche Marketing Authorization For MabThera SC For Patients...
(Source: Halozyme Therapeutics Inc) MabThera SC offers a faster administration time for patients in Europe while potentially saving valuable time for health systems SAN DIEGO, March 28, 2014...
View ArticleBaxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of...
LONDON, March 22, 2013 /PRNewswire/ -- Baxter International Inc. (NYSE: BAX) and Halozyme Therapeutics, Inc., (NASDAQ: HALO) today announced that the European Medicines Agency's Committee for Medicinal...
View ArticleHalozyme Therapeutics to Present at the Barclays 2013 Global Healthcare...
SAN DIEGO, March 5, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Barclays 2013 Global Healthcare Conference in Miami, FL. on March 12, 2013 at 4:15 p.m....
View ArticleHalozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2013...
SAN DIEGO, May 7, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas on Tuesday, May 14,...
View ArticleHalozyme Therapeutics Enters A Global Collaboration With Janssen To Develop...
Halozyme Therapeutics, Inc. Logo. Facebook Twitter Pinterest × Halozyme Therapeutics, Inc. Logo. SAN DIEGO, Dec. 17, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that...
View ArticleHalozyme Therapeutics Enters A Global Collaboration With Janssen To Develop...
(Source: Halozyme Therapeutics Inc) SAN DIEGO, Dec. 17, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that it has entered into a worldwide Collaboration and License...
View ArticleRoche's Commercial Launch Of MabThera SC Triggers Milestone Payment To...
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.) × Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.) SAN DIEGO, June 25, 2014 /PRNewswire/ -- Halozyme...
View ArticleRoche's Commercial Launch Of MabThera SC Triggers Milestone Payment To...
(Source: Halozyme Therapeutics Inc) MabThera SC offers a faster administration time for patients in Europe while potentially saving valuable time for health systems SAN DIEGO, June 25, 2014...
View Article
